Helix BioPharma Closes Private Placement

Helix BioPharma (TSX:HBP) announced it closed a private placement financing option, which resulted in gross proceeds of $1,311,000.
As quoted in the press release:

The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

Click here to read the full press release.

Source: www.marketwired.com